Source 1primary paper2025MED
Toolkit/1-Pyrenebutyric acid N-hydroxysuccinimide ester functionalisation
1-Pyrenebutyric acid N-hydroxysuccinimide ester functionalisation
Also known as: Pyr-NHS, Pyr-NHS linker
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
functionalising them with a 1-Pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) to enable effective antibody immobilisation
Usefulness & Problems
Why this is useful
Pyr-NHS is used to functionalise the graphene foam electrode surface so antibodies can be immobilised effectively. The abstract links this stable functionalisation to the assay's analytical performance.; stable functionalisation of graphene foam electrodes; antibody immobilisation on electrode surfaces
Source:
Pyr-NHS is used to functionalise the graphene foam electrode surface so antibodies can be immobilised effectively. The abstract links this stable functionalisation to the assay's analytical performance.
Source:
stable functionalisation of graphene foam electrodes
Source:
antibody immobilisation on electrode surfaces
Problem solved
It solves the surface-chemistry problem of attaching capture antibodies to the electrode.; enables effective antibody immobilisation on 3D graphene foam electrodes
Source:
It solves the surface-chemistry problem of attaching capture antibodies to the electrode.
Source:
enables effective antibody immobilisation on 3D graphene foam electrodes
Problem links
enables effective antibody immobilisation on 3D graphene foam electrodes
LiteratureIt solves the surface-chemistry problem of attaching capture antibodies to the electrode.
Source:
It solves the surface-chemistry problem of attaching capture antibodies to the electrode.
Published Workflows
Objective: Develop a point-of-care electrochemical biosensing assay for sensitive detection of Alzheimer's disease biomarkers Aβ42 and Aβ40 using Pyr-NHS-functionalised 3D graphene foam electrodes.
Why it works: The abstract attributes performance to stable Pyr-NHS functionalisation, the superior conductivity and larger surface area of 3D graphene foam, and optimisation of antibody concentration for immobilisation.
stable antibody immobilisation via Pyr-NHS functionalisationreduced non-specific binding via BSA blockingenhanced electrochemical performance via conductive high-surface-area 3D graphene foamsurface functionalisationantibody immobilisationelectrochemical DPV readoutinterference testingspiked plasma validation
Stages
- 1.Electrode functionalisation and assay assembly(library_build)
This stage creates the functional biosensor surface needed for analyte detection.
Selection: Functionalise 3D graphene foam electrodes with Pyr-NHS, bind Aβ42 and Aβ40 antibodies, and block with BSA to create the assay surface.
- 2.Electrochemical performance measurement(functional_characterization)
This stage quantifies whether the assembled biosensor performs adequately for Aβ42 and Aβ40 detection.
Selection: Use DPV to measure stability and analyte detection performance.
- 3.Interference assessment(counter_screen)
This stage checks whether the biosensor signal is affected by a related non-target biomarker.
- 4.Spiked plasma validation(confirmatory_validation)
This stage tests whether the biosensor retains utility in a more realistic biological sample matrix than buffer-only measurements.
Selection: Validate assay performance in spiked-diluted human plasma.
Steps
- 1.Functionalise 3D graphene foam electrodes with Pyr-NHSelectrode substrate and surface linker
Enable effective and stable antibody immobilisation on the electrode surface.
Surface functionalisation is performed first because it prepares the graphene foam for subsequent antibody binding.
- 2.Bind Aβ42 and Aβ40 antibodies to the functionalised electrodecapture interface assembly
Create analyte-specific recognition surfaces for Aβ42 and Aβ40 detection.
Antibody binding follows Pyr-NHS functionalisation because the linker chemistry is used to enable antibody immobilisation.
- 3.Block the electrode surface with BSAblocking reagent
Minimise non-specific binding on the electrode surface.
Blocking is performed after antibody immobilisation to reduce non-specific interactions before measurement.
- 4.Measure biosensor performance by DPVbiosensor under test and readout method
Assess stability and detection performance for Aβ42 and Aβ40.
Electrochemical measurement is performed after assay assembly because the completed biosensor must be read out to determine performance.
- 5.Test interference from tau217 proteinbiosensor under specificity challenge
Evaluate whether a non-target AD-related protein interferes with Aβ detection.
Interference testing follows primary performance measurement to check specificity after sensitive detection has been established.
- 6.Validate the biosensor in spiked-diluted human plasmabiosensor under matrix validation
Confirm assay function in a human plasma matrix.
Plasma validation is performed after analytical characterization to test whether the assay remains usable in a more realistic sample matrix.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
It requires a graphene foam electrode surface and subsequent antibody binding steps.; must be applied to the graphene foam electrode before antibody binding
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The biosensor achieved attomolar-scale limits of detection of 252 aM for Aβ42 and 395 aM for Aβ40.
The biosensor exhibited a low limit of detection (LOD) with 252 aM for Aβ42 and 395 aM for Aβ40
limit of detection for Aβ40 395 aMlimit of detection for Aβ42 252 aM
The biosensor covered a 0.125 fM-1 nM linear range for Aβ42 and a 0.125 fM-100 pM linear range for Aβ40.
covering 0.125 fM-1 nM and 0.125 fM-100 pM linear ranges, respectively
linear range for Aβ40 0.125 fM-100 pMlinear range for Aβ42 0.125 fM-1 nM
The reported analytical performance was attributed to stable Pyr-NHS functionalisation, the superior conductivity and larger surface area of 3D graphene foam, and optimisation of antibody concentration for immobilisation.
This excellent analytical performance was attributed to the stable Pyr-NHS functionalisation, the 3D graphene foam enabling superior conductivity and a larger surface area on the working electrode, and the optimisation of antibody concentration for immobilisation.
DPV measurements showed satisfactory biosensor stability over 12 days with RDS upper limit below 10%.
Differential Pulse Voltammetry (DPV) measurements showed satisfactory stability over 12 days (RDS upper limit was <10%)
RDS upper limit 10 %stability duration 12 days
A Pyr-NHS-functionalised 3D graphene foam electrode biosensor enabled highly sensitive and specific electrochemical detection of Aβ42 and Aβ40.
Differential Pulse Voltammetry (DPV) measurements showed satisfactory stability over 12 days (RDS upper limit was <10%) and highly sensitive and specific detection of Aβ42 and Aβ40, with insignificant interference of tau217 protein.
Approval Evidence
1 source1 linked approval claimfirst-pass slug 1-pyrenebutyric-acid-n-hydroxysuccinimide-ester-functionalisation
functionalising them with a 1-Pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) to enable effective antibody immobilisation
Source:
mechanistic attributionsupports
The reported analytical performance was attributed to stable Pyr-NHS functionalisation, the superior conductivity and larger surface area of 3D graphene foam, and optimisation of antibody concentration for immobilisation.
This excellent analytical performance was attributed to the stable Pyr-NHS functionalisation, the 3D graphene foam enabling superior conductivity and a larger surface area on the working electrode, and the optimisation of antibody concentration for immobilisation.
Source:
Comparisons
Source-backed strengths
described as stable functionalisation; contributed to excellent analytical performance
Source:
described as stable functionalisation
Source:
contributed to excellent analytical performance
Ranked Citations
- 1.